<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Kottilil, Shyam</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Interferon- and RBV-Free Treatment with LDV and SOF is Efficacious in Patients Coinfected with HCV and HIV</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">25-25</style></pages><abstract><style  face="normal" font="default" size="100%">Patients coinfected with hepatitis virus C (HCV) and HIV tend to respond poorly to interferon-based therapy and are at higher risk of treatment-related toxicities and adverse events. Treatment options are limited. There is some evidence that interferon-free therapy may work as well in patients who are HIV positive or negative. This article discusses a phase 2 study looking at the treatment option of sofosbuvir and the HCV NS5A inhibitor ledipasvir.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>